Micron (MU) earnings preview for Q2 FY26. Wall Street forecasts $8.74 EPS and $19.03B revenue. Stock up 55% YTD with analysts raising price targets to $500.
Browsing: Stocks
Trump demands emergency Fed rate cut at March meeting, but markets show 99% chance rates stay unchanged. Oil prices and inflation complicate Fed decision.
AI crypto tokens NEAR, FET, and WLD surged 10-20% after Nvidia CEO Jensen Huang’s GTC keynote revealed $1T chip demand and highlighted agentic AI systems.
Bitcoin tested $75,000 driven by derivatives activity while crypto markets posted broad gains. Stock futures declined ahead of Wednesday’s Fed meeting.
Israeli reporter Emanuel Fabian received death threats from Polymarket bettors over his Iran strike coverage tied to a $17M wager. Polymarket banned those involved.
PayPal (PYPL) has collapsed 85% from its 2021 high. With a new CEO, weak Q4 growth, and a fading Stripe rally, is this stock a steal or stay away?
Exxon Mobil (XOM) stock climbs 1.8% following consecutive analyst upgrades from Barclays and Piper Sandler citing Iran war oil supply disruption risks.
Arista Networks (ANET) garners 93% buy ratings from analysts with a $177.50 target, driven by AI networking demand and 42.8% net margins.
Barclays upgrades Nike (NKE) to overweight with $73 target, calling a potential bottom as the stock trades near decade lows ahead of March 31 earnings.
Duolingo (DUOL) stock climbed 3.1% Monday as crude oil dropped 4% and market sentiment improved. Despite the gain, shares are down 42.5% in 2026.
Wells Fargo’s Aaron Rakers maintains Strong Buy ratings on Marvell (MRVL), Micron (MU), and Rambus (RMBS) with elevated price targets on AI demand.
Ciena (CIEN) stock surges 450% in 12 months to 25-year highs, fueled by AI-driven networking demand, record earnings, and strong institutional support.
IREN stock rises 6.3% Monday on high volume despite Q4 earnings miss. Analysts maintain Moderate Buy rating with $71.69 target amid AI infrastructure growth.
PayPay (PAYP) jumped 16% after its Nasdaq IPO debut. Macquarie assigned an Outperform rating with a $22.90 target, highlighting 65% QR market dominance.
Olema Pharmaceuticals (OLMA) stock gained 8.5% after beating Q4 estimates. Stifel keeps Buy rating at $48. Full breakdown of analyst views and trial data.